Brief: Scynexis Issues A Voluntary Nationwide Recall Of Brexafemme Due To Potential For Cross Contamination
Sept 27 (Reuters) - SCYNEXIS Inc SCYX.O :
* SCYNEXIS ISSUES A VOLUNTARY NATIONWIDE RECALL OF
BREXAFEMME®
(IBREXAFUNGERP TABLETS) DUE TO POTENTIAL FOR CROSS CONTAMINATION
WITH A NON-ANTIBACTERIAL ß-LACTAM DRUG SUBSTANCE
* TO DATE, CO HAS NOT RECEIVED ANY REPORTS OF ADVERSE EVENTS
ESTABLISHED TO BE DUE TO POSSIBLE BETA-LACTAM CROSS
CONTAMINATION.
* SCYNEXIS WAS MADE AWARE OF POTENTIAL CROSS-CONTAMINATION
RISK
Source text for Eikon: ID:nGNX21yV9y
Further company coverage: SCYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview